| HOME >> MEDICINE >> TECHNOLOGY |
Ranbaxy fails in its attempt to enter the Russian market 104
Opportunities for the generics industry 105
Russia - Small molecule brand erosion 106
Overview of drugs analyzed 106
Mean level of brand erosion in Russia 107
Brand erosion in the Russian retail and hospital setting 109
Brand erosion by therapy area in Russia 111
Brand erosion by drug formulation in Russia 113
Russia - Biosimilars market dynamics 115
Drivers and resistors to biosimilar uptake in Russia - development costs and lack of regulation is attractive to biosimilar manufacturers 115
Biosimilars available in Russia 117
Biosimilar filgrastim 118
Opportunities for the biosimilar industry 120
Biosimilars in development internationally 122
Russia presents challenges for monoclonal antibody manufacturers 123
6. Russia - Pharmaceutical industry infrastructure analysis 125
Russia - Key findings 125
Russia - Pharmaceutical infrastructure overview 126
The new pharmaceutical bill will lead to enforced pricing and preferential listing of domestically manufactured generics 126
Domestic GMP standards are poor, but are set to improve 126
Russia is becoming a hotspot for clinical trials 128
Russia - key company infrastructure 130
Novartis 131
Sanofi-Aventis 134
Johnson & Johnson 137
Roche 140
Pharmstandard 143
Bayer Schering 146
Servier 149
Teva 152
Merck & Co. 155
Gedeon Richter 158
Gedeon Richter boosts its Russian presence 160
7. Russia - Bibliography 161
Russia - Executive summary 161
Publications and online articles 161
Datamonitor reports and products 162
Russia - Socio-demographic and economic analysis 162
Publications and online articles 162
Publications and online articles 165
Russia - Heal
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |